eISSN: 2688-6650
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Dulaglutide: A Review of a New Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus

Mohamed Teleb, Ngamdu Sumayin, Sarmad Said

Department of Internal Medicine, Texas Tech University Health Science Center, Paul L. Foster School of Medicine, El Paso, TX, USA

Med Sci Rev 2014; 1:18-23

DOI: 10.12659/MSRev.893152

Available online:

Published: 2014-12-02


Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective therapeutic approach to obtain better glycemic control in type-2 diabetes mellitus patients. Various preclinical and clinical studies demonstrated the efficacy in cardiovascular benefits beside tight glycemic control. In September 2014 the Food and Drug Administration (FDA) approved the GLP-1 RA, Dulaglutide, for the treatment of type-2 diabetes mellitus. The series of AWARD (Assessment of Weekly Administration of LY2189265 in Diabetes) studies compared Dulaglutide with other anti-diabetic agents, with promising results, including weight reduction and controlled systolic blood pressure (BP). The safety panel of Dulaglutide demonstrated a tolerable adverse effect profile, mainly gastrointestinal.

Keywords: Awards and Prizes, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Incretins